📰 Dose Escalation News
Page 3 - Dose Escalation News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Dose Escalation. Real-time updates on events, politics, business and more.
June 2, 2023
An oral presentation titled "Phase 1/2 Study of DF1001, an Immune Modulating TriNKET® Targeting HER2, in Patients with Advanced Solid Tumors: Phase 1 DF1001 Monotherapy Dose Escalation Results"
May 25, 2023
- Enrollment progress update from ongoing China Phase 1 trial of TERN-701 to be presented at ASCO 2023 - China Phase 1 trial completed enrollment of Cohort 5 in the Dose Escalation phase FOSTER... | May 25, 2023
May 8, 2023
08.05.2023 - ─ Tuspetinib Dose Escalation and Dose Exploration Trial Completed and Delivered Clinical Responses as Monotherapy Over Four Dose Levels in Very Difficult to Treat AML Patient Populations ─ ─ Doublet of Tuspetinib and Venetoclax Dosing Underway for ...
December 12, 2022
Four oral presentations presented at ASH highlight data evaluating investigational epcoritamab for the treatment of relapsed/refractory (R/R) foll...
December 12, 2022
/PRNewswire/ -- Ichnos Sciences Inc., a global clinical-stage biotechnology company developing innovative multispecific immune cell engager antibodies in...
December 11, 2022
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced data from multiple clinical trials evaluating epcoritamab (DuoBody®-CD3xCD20), an investigational...
October 12, 2022
11.10.2022 - - NEObody technology platform enables dynamic targeting of a distinct epitope of CTLA-4 for enhanced safety and efficacy - - Data from phase 1b/2 studies in heavily pre-treated patients showcase differentiated safety profile of ... Seite 1
October 8, 2022
Gurugram (Haryana) [India], October 8 (ANI/PRNewswire): Premas Biotech, developer of technologies & bioprocesses for novel proteins, today announced that Oravax Medical Inc., a US-based company that Premas Biotech is a shareholder in, reported positive preliminary data from its Phase 1 trial in South Africa of an oral Covid-19 vaccine candidate. Preliminary Phase 1 trial results from the first cohort include: - Significant antibody response (2-6 fold over baseline) as measured by multiple ma...
August 26, 2022
Byondis Initiates Phase I Study of Next Generation Antibody-Drug Conjugate BYON3521 ·        BYON3521 Targets c-MET, Widely Overexpressed in Solid Tumors·        Therapy Uses Proprietary Technologies Designed to Enhance Efficacy...
August 25, 2022
BYON3521 Targets c-MET, Widely Overexpressed in Solid TumorsTherapy Uses Proprietary Technologies Designed to Enhance Efficacy and SafetyNIJMEGEN, Netherlands, Aug. 25, 2022 /PRNewswire/ --